{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T18:34:32Z","timestamp":1715538872722},"reference-count":0,"publisher":"Portland Press Ltd.","issue":"s3","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[1976,1,1]]},"abstract":"<jats:p>1. The role of arginine-vasopressin in the pathogenesis of malignant deoxycorticosterone (DOC) hypertension of rats was investigated.<\/jats:p>\n               <jats:p>2. In rats with malignant DOC hypertension plasma arginine-vasopressin concentrations increased more than tenfold subsequent to volume depletion and a rise of serum osmolality.<\/jats:p>\n               <jats:p>3. The injection of a specific antibody serum for arginine-vasopressin caused a marked fall of blood pressure in rats with malignant DOC hypertension, whereas the injection of angiotensin II antiserum did not affect blood pressure.<\/jats:p>\n               <jats:p>4. In rats exhibiting a benign course of DOC hypertension plasma concentrations of arginine-vasopressin were increased threefold in comparison with normotensive control rats; the injection of an arginine-vasopressin antiserum induced a significant but small fall of blood pressure.<\/jats:p>\n               <jats:p>5. It is concluded that in the pathogenesis of malignant DOC hypertension arginine-vasopressin might play the role that the renin\u2014angiotensin system plays in the pathogenesis of malignant renal hypertension.<\/jats:p>","DOI":"10.1042\/cs051045s","type":"journal-article","created":{"date-parts":[[2015,8,7]],"date-time":"2015-08-07T10:31:32Z","timestamp":1438943492000},"page":"45s-48s","update-policy":"http:\/\/dx.doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Vasopressin and Malignant Deoxycorticosterone Hypertension in Rats"],"prefix":"10.1042","volume":"51","author":[{"given":"J.","family":"M\u00f6hring","sequence":"first","affiliation":[{"name":"Department of Pharmacology, University of Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"M\u00f6hring","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Petri","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Haack","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/portlandpress.com\/clinsci\/article-pdf\/51\/s3\/45s\/817224\/cs051045s.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/portlandpress.com\/clinsci\/article-pdf\/51\/s3\/45s\/817224\/cs051045s.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,27]],"date-time":"2019-10-27T00:38:37Z","timestamp":1572136717000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/51\/s3\/45s\/101611\/Vasopressin-and-Malignant-Deoxycorticosterone"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1976,1,1]]},"references-count":0,"journal-issue":{"issue":"s3","published-print":{"date-parts":[[1976,1,1]]}},"URL":"https:\/\/doi.org\/10.1042\/cs051045s","relation":{},"ISSN":["0144-4107"],"issn-type":[{"value":"0144-4107","type":"print"}],"subject":[],"published":{"date-parts":[[1976,1,1]]}}}